Radiopharmaceuticals

Scaling for a New Era: The Rise of Radiopharma

6 days ago talkbio0Tagged Clinical Trials, CROs, Diagnostics, Funding, Lutetium-177, M&A, Neoplasms, Pet Animal, precision oncology, radioligand therapy, Radiopharmaceuticals, radiotheranostics, Research Infrastructure, supply chain, targeted alpha therapy

radiopharmaceuticals; radioligand therapy; oncology; precision oncology; targeted alpha therapy; Lutetium-177; Actinium-225; clinical trials; radiotheranostics; M&A; biotech funding; supply chain; infrastructure; CROs; companion diagnostics

Ratio Therapeutics Appoints Marcel Reichen as Chief Strategy Officer

2 months ago talkbio0Tagged Cancer Therapeutic Procedure, Chief Strategy Officer, Drug Industry, Marcel Reichen, Neoplasms, Precision - temporal, radioligand therapy, Radiopharmaceuticals, Ratio Therapeutics, Strategic Growth

Ratio Therapeutics; Marcel Reichen; Chief Strategy Officer; radiopharmaceuticals; oncology; radioligand therapy; pharmaceutical industry; cancer treatment; strategic growth; precision oncology

Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO

4 months ago talkbio0Tagged Appointments, biotech leadership, Cancer Therapeutic Procedure, CEO, Commissioner, Hahn, Nucleus RadioPharma, Radiopharmaceuticals, supply chain, United States Food and Drug Administration

Nucleus RadioPharma; Stephen Hahn; FDA Commissioner; CEO appointment; radiopharmaceuticals; cancer therapy; supply chain; biotech leadership

NUCLIDIUM Sees Copper Isotopes as Future of Radiopharmaceuticals, Raises CHF 79M to Advance Clinical Development

5 months ago talkbio0Tagged cancer diagnostics, cancer therapeutics, copper isotopes, Malignant neoplasm of breast, Metastatic Prostate Carcinoma, Neoplasms, Neuroendocrine Tumors, NUCLIDIUM, NuriPro, Radiopharmaceuticals, Series B financing, Theranostics, TraceNET

NUCLIDIUM; copper isotopes; radiopharmaceuticals; Series B financing; Cu-NuriPro; NuriPro; TraceNET; oncology; theranostics; metastatic prostate cancer; neuroendocrine tumors; breast cancer; cancer diagnostics; cancer therapeutics

ITM Reports Positive Phase 3 Data for Radiopharmaceutical ITM-11 in Neuroendocrine Tumors, Challenging Novartis’ Lutathera

10 months ago talkbio0Tagged ITM-11, Lutathera, Neoplasms, Neurosecretory Systems, Novartis, Phase 3 COMPETE trial, Radiopharmaceuticals

ITM-11, radiopharmaceutical, Phase 3 COMPETE trial, neuroendocrine tumors, Lutathera, Novartis

Eli Lilly Expands Oncology and Metabolic Disease Portfolio with Strategic Partnerships

10 months ago talkbio0Tagged AdvanCell, alpha therapies, cardiometabolic diseases, cellular targeting, Eli, Eli Lilly, MASH, OliX, Radiopharmaceuticals, strategic collaborations

Eli Lilly, AdvanCell, OliX Pharmaceuticals, targeted alpha therapies, radiopharmaceuticals, MASH, cardiometabolic diseases, strategic collaborations

Eli Lilly Expands Pipeline with Strategic Deals in MASH and Cancer Therapies

10 months ago talkbio0Tagged AdvanCell, alpha therapies, Cancer Therapeutic Procedure, cardiometabolic diseases, cellular targeting, Eli, Eli Lilly, Interferes with, MASH, OliX, Radiopharmaceuticals, RNA

Eli Lilly, OliX Pharmaceuticals, AdvanCell, MASH, targeted alpha therapies, radiopharmaceuticals, RNA interference, cardiometabolic diseases, cancer treatment